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Abstract
DLC2 (deleted in liver cancer 2), a Rho GTPase-activating protein, was previously shown to be underexpressed in human
hepatocellular carcinoma and has tumor suppressor functions in cell culture models. We generated DLC2-deficient mice to
investigate the tumor suppressor role of DLC2 in hepatocarcinogenesis and the function of DLC2 in vivo. In this study, we
found that, unlike homologous DLC1, which is essential for embryonic development, DLC2 was dispensable for embryonic
development and DLC2-deficient mice could survive to adulthood. We also did not observe a higher incidence of liver
tumor formation or diethylnitrosamine (DEN)-induced hepatocarcinogenesis in DLC2-deficient mice. However, we observed
that DLC2-deficient mice were smaller and had less adipose tissue than the wild type mice. These phenotypes were not due
to reduction of cell size or defect in adipogenesis, as observed in the 190B RhoGAP-deficient mouse model. Together, these
results suggest that deficiency in DLC2 alone does not enhance hepatocarcinogenesis.
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Introduction
Hepatocellular carcinoma (HCC) is a primary malignancy and
is one of the most common cancers in Asia and Africa. Infection
with hepatitis B or C virus infection and exposure to aflatoxin B1
have been well documented as the major causes. However, the
underlying molecular mechanisms leading to the development and
progression of HCC remain unclear.
Inactivation of tumor suppressor genes is a hallmark of cancer
cells. In a quest for tumor suppressors involved in hepatocarcin-
ogenesis, we identified a novel gene DLC2 (deleted in liver cancer
2) on chromosomal region 13q12.3, which is frequently lost in
HCCs [1]. Similar to its homolog DLC1, DLC2 is underexpressed
in human HCCs and has tumor suppressor functions in cultured
cells [1,2].
DLC1 and DLC2 are Rho GTPase-activating proteins (GAPs).
They have three functional domains, a catalytic RhoGAP domain
[1,3], a sterile alpha motif (SAM) protein interaction domain [4,5]
and a lipid-binding StAR-related lipid-transfer (START) domain
[6,7]. The Rho family GTPases have 18 members, including the
three well-studied representatives, Rac1, RhoA, and Cdc42. These
small GTPases regulate various cellular signaling pathways [8,9].
It has been suggested that the Rho proteins play important roles in
oncogenic transformation mediated by Ras and other oncopro-
teins by regulating actin cytoskeleton organization, cell prolifer-
ation and cell survival [10,11]. Also, they stimulate tumor cell
invasion and metastasis [9]. Rho GTPase-activating proteins
(GAPs) inactivate them by converting the active GTP-bound state
to the inactive GDP-bound one through activation of the intrinsic
GTPase activity of Rho proteins. GAPs have therefore been
suggested to be tumor suppressors which counteract the oncogenic
potential of Rho proteins.
There have been several lines of in vitro evidence to support the
tumor suppressor role of these two Rho GAP proteins, DLC1 and
DLC2 [1,2,3,5,12,13,14,15,16]. Animal models which could be
exploited to investigate the tumor suppressor functions of these two
proteins are still limited. Durkin et al. [17] has generated a DLC1-
deficient mouse model to study the biological functions of DLC1.
However, the DLC1 deficiency leads to embryonic lethality by
midgestation. Sordella et al [18] showed that embryos lacking
p190B RhoGAP were about 30% smaller in size and provided
evidence to suggest that this reduction in embryo size was due to
reduction in cell size. They also demonstrated that murine
embryonic fibroblasts derived from these embryos were defective
inadipogenesiswhencomparedwiththewildtypecounterpart[19].
In this study, we generated DLC2-deficient mice to investigate
the biological functions of DLC2 and its role in hepatocarcino-
genesis in vivo. Unlike the DLC1 knockout model, DLC2 was
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could survive to adulthood. DLC2-deficient mice did not show
higher incidence of hepatocarcinogenesis or diethylnitrosamine
(DEN)-induced hepatocarcinogenesis. However, DLC2-deficient
mice were significantly smaller and had less adipose tissue than the
wild type mice. Analysis of adipogenesis of DLC2-deficient and
wild type murine embryonic fibroblasts did not show significant
difference between them. Also, we did not observe any significant
difference in the cell size between G1 phase DLC2-deficient and
wild type immortalized fibroblasts with flow cytometry.
Materials and Methods
Generation of DLC2-deficient mice
A PAC clone containing the mouse Dlc-2 genomic region was
obtained from the Sanger Centre (Cambridge, United Kingdom).
To construct the mouse Dlc-2 gene targeting vector, a 2.8 kb
EcoRI/BamHI fragment, which is 39 to exon 5, was cloned into the
EcoRI/BamHI site of pPNT (Figure 1a). A pair of primers
(forward, 59-ttactcgagttgctgatgcacaggtcttc; reverse, 59-ttactcgagtt-
ctcgtgttaggaatgggg) was used to amplify a genomic region, 2.7 kb
in size and 59 to exon 5 (Figure 1a). The fragment was then cloned
into pPNT [20]. The targeting vector was linearized with NotI and
was electroporated into the AB2.2 embryonic stem (ES) cell line
(129s7/SvEBrd-Hprt b-m2), and the cells were cultured in ES cell
culture medium supplemented with G418 and fialuridine.
Resistant clones were analyzed by Southern blotting (see below)
to identify DLC2-targeted clones.
All research involving animal work was approved by the
Committee on the Use of Live Animals in Teaching and Research
(CULATA) of the University of Hong Kong. Cells from these
clones were injected into C57BL/6N blastocysts. Chimeras were
mated with C57BL/6N mice, and offspring containing DLC2-
targeted allele were identified. Mice with mixed genetic back-
grounds were back-crossed to C57BL/6N for at least five
generations.
Figure 1. Gene targeting to generate DLC2-deficient mice. (a) Schematic diagram to show gene targeting strategy. Black boxes, exons of the
mouse DLC2 gene (exon numbers are written at the top); gray boxes, DNA sequence of neomycin resistance gene of the targeting construct; white
box, DNA sequence of thymidine kinase gene of the targeting construct. Restriction enzyme digestion sites: B, BamHI; Bg, BglII; E, EcoRI; N, NcoI; only
diagnostic restriction sites are shown for simplicity. (b) Southern blot analysis. BglII digestion was probed with 59 probe as indicated; sizes of
diagnostic bands: wild type allele, 4.7 kb; targeted allele, 5.7 kb. NcoI digestion was probed with 39 probe as indicated; sizes of diagnostic bands: wild
type allele, 9.1 kb; targeted allele, 5.7 kb. (c) PCR genotyping; sizes of bands: wild type allele, 414 bp; targeted allele, 339 bp. (d) RT-PCR to detect
DLC2 expression in heart, liver and skeletal muscle.
doi:10.1371/journal.pone.0006566.g001
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For Southern blot analysis, two probes, 59 and 39 external, were
used (Figure 1a). BglII digestion was probed with the 59 probe and
the sizes of diagnostic bands were 4.7 kb for the wild type allele
and 5.7 kb for the targeted allele. NcoI digestion was probed with
the 39 probe, and the sizes of diagnostic bands were 9.1 kb for the
wild type allele and 5.7 kb for the targeted allele.
Two pairs of primers were used for PCR genotyping. For detection
of the wild type allele, forward (59-AATGGAAGCACCATG-
TAGCC)andreverse primer 59-AATGGAAGCACCATGTAGCC)
were used, with expected size of the PCR product 414 bp. For
detection of the targeted allele, forward (59-CTGGGAAGACAGG-
GAACAAA) and reverse primers (59-GGGGGAACTTCCTGAC-
TAGG) were used, with expected size of the PCR product being,
339 bp.
Forsemi-quantitative RT-PCRanalysis,total RNAwasprepared
from mouse tissues using the TRIzol reagent (Invitrogen). First-
strand cDNA was synthesized from 1 mg of total RNA using
random hexamers with GeneAmp RNA PCR Kit (Applied
Biosystems, Foster City, CA). Two ml of cDNA was then used for
detecting the expression levels of DLC1, DLC2 and DLC3 using the
following primers: For mouse DLC1 gene, forward primer (59-
CCCATTCAGTCAGTCCACCTTGA) and reversed primer (59-
GAGTCTCCCTCGTCGGAAAAC) were used; For mouse DLC2
gene, forward primer (59-GATGAGAAACACAGCCAGCA) and
reverse primer (59-GTTGGGTATCTGGACGCACT) were used;
For DLC3, forward primer (59-TCCACAGGCAGCCATGCCAG)
and reversed primer (59-TCTTGCTCAAGATCCTGGGCC)
were used. PCR condition was as follows: denaturation at 95uC
for 15 min, followed by 25 cycles (DLC1 and DLC2) or 27 cycles
(DLC3)of denaturation for30 sec,annealingat55uC for30 secwith
extension at 72uC for 30 sec and a final extension at 72uC for
10 min. PCR products were resolved in 1.2% agarose gel.
Metabolic cage experiment
Mice were individually housed in metabolic cages in a 12:12-hour
dark-light cycle and were fed adlibitum. Water and food consumption,
and urine and faeces output were measured for 2 days.
Diethylnitrosamine (DEN) treatment of mice
The hepatocarcinogenesis protocol was as follows. The 15-day-
old male DLC2 homozygous knockout mice and wild type mice
were injected intraperitoneally with 25 mg/kg DEN in sterile PBS.
At 35 weeks of age, mice were sacrificed and their livers were
harvested and examined. The livers were then fixed in 4%
formaldehyde in PBS, embedded in paraffin and cut into 4-mm
sections for histological examination.
Preparation of murine embryonic fibroblasts (MEFs) and
establishment of cell lines
Pregnant mice were sacrificed at 13.5 days past coitus (dpc). The
embryos were dissected from the uterus, and the extra-embryonic
membranes and viscera were removed. The embryos were cut into
small pieces, and soaked for 30 min in 4 ml of 0.25% trypsin-
EDTA at room temperature. Trypsinization was inactivated with
a-modified Eagle medium (aMEM) supplemented with 10% heat-
inactivated FBS, 50 U of penicillin per ml, and 50 mgo f
streptomycin per ml. The cells were suspended by pipetting and
passed through a strainer. Standard procedures were used to
establish immortalized fibroblast cell lines [21]. Briefly, cells were
passaged every 3 days in DMEM supplemented with 10% calf
serum and antibiotics at a density of 10
6 cells per 10 cm dish.
Media were changed on the subsequent day. Stable immortalized
cell lines were established after 30 to 50 passages.
Measurement of cell sizes
T h er e l a t i v es i z e so fDLC2
+/+ and DLC2
2/2 cells were determined
with flow cytometry. Briefly, cells were BrdU-labeled using FITC
BrdU Flow Kit (BD Pharmingen
TM,N J ,U S A ) .G 1p o p u l a t i o no f
cells was gated and the forward light scatter (FSC) of 5000 G1-cells
was determined. FSC was used to determine the relative cell sizes.
Induction of adipocyte differentiation
For induction of adipocyte differentiation, MEF cells used were
within two passages. Induction of adipocyte differentiation was
performed as previously described [19]. Cells were cultured on 6-
well plates and propagated to confluence. Two days later, the
medium was replaced with standard differentiation induction
medium (a-MEM containing 0.5 mM isobutylmethylxanthine,
1 mM dexamethasone, 5 mg of insulin per ml, 10% FBS, 50 U of
penicillin per ml, and 50 mg of streptomycin per ml, and the
medium was renewed every other day. The cells were induced for
8 days before analysis.
The cells were fixed in 10% formalin, rinsed twice with
phosphate-buffered saline (PBS), and stained with Oil-Red O
staining solution (0.5% Oil-Red O in isopropyl alcohol solution-
distilled water [60:40]) for 30 min at 37uC and then washed with
distilled water three times. Adipogenesis in Oil-Red-O-stained
MEF was quantified by measuring the absorbance of light at
510 nM after extraction with isopropyl alcohol.
Rhotekin binding assay
Cells were lysed in 500 ml of lysis buffer containing 50 mM Tris
(pH 7.4), 10 mM MgCl2, 500 mM NaCl, 1% Triton X-100, 0.1%
SDS, 0.5% sodium deoxycholate, 10 mg/ml of aprotinin, 10 mg/
ml of leupeptin, and 1 mM PMSF. The lysates were cleared by
centrifugation at 12,000 6 g for 10 min at 4uC, and 500 mgo f
each lysate was incubated with 45 mg of GST-RBD (GST fusion
protein containing RhoA-binding domain of Rhotekin) bound to
glutathione-Sepharose beads (Amersham Pharmacia) for 1 h.
After binding, the samples were washed with lysis buffer for three
times. Bound proteins were fractionated on 12% SDS/PAGE and
immunoblotted with polyclonal antibody for RhoA (Santa Cruz
Biotechnology). Total cell lysate was also analyzed with anti-RhoA
antibody as a loading control. The level of active RhoA was
determined after normalization with the total RhoA present in the
cell lysates.
Immunofluorescence staining
Cells were grown on cover slips and were rinsed in PBS, fixed
with 4% paraformaldehyde in PBS for 15 minutes at room
temperature, permeabilized with 0.5% Triton X-100 in PBS for 5
minutes and blocked with 5% bovine serum albumin in PBS. After
washing with PBS, cells were then incubated with paxillin antibody
(Sigma), followed by FITC-conjugated secondary antibody at room
temperature. F-actins were stained with tetramethylrhodamine B
isothiocyanate-labeled phalloidin (Sigma) for 20 min at room
temperature, and the nuclei were stained by DAPI. Cells were
mounted with Vectashield antifade solution (Vector Laboratories).
Results
Generation of DLC2-deficient mice
To study the function of the DLC2 in vivo and the role of DLC2 in
hepatocarcinogenesis, we generated DLC2-deficent mice. Disruption
the mouse DLC2 gene was achieved by homologous recombination
in embryonic stem(ES) cells. Inthe recombination, exon5, thelargest
exon of DLC2 gene, was replaced by the neomycin resistance gene of
the targeting vector (Figure 1a). Two targeted ES clones were used to
DLC2 and Hepatocarcinogenesis
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2/2 mice
did not express the DLC2 mRNAasdetectedbyRT-PCR onselected
tissues, heart, liver and skeletal muscle (Figure 1d).
DLC2-deficient mice were anatomically normal but
smaller and had less adipose fat
Unlike the DLC1
2/2 mice, which died in embryonic stage,
DLC2
2/2 mice could survive to adulthood. This suggests that
DLC2 is dispensable for embryonic development. Anatomical
analysis showed that DLC2
2/2 mice were normal (at 30 week-old),
however DLC2
2/2 mice were smaller in size and lighter in weight
(p=0.01) (Figure 2a) and had less adipose tissue than wild type mice
(p=0.02) (Figure2b& 2c).Wewantedtoexcludethe possibility that
DLC2
2/2 mice might eat less food than DLC2
+/+ mice and this
might contribute to their smaller body size. We therefore performed
metabolic cage experiment to investigate whether there were any
Figure 2. DLC2-dificient mice were smaller and had less adipose fat. (a) Body weight. (b) Weight of epididymal fat pads. In (a) and (b), mean
values6standard errors and p-values are shown. P-values were calculated by unpaired Student’s t test. (c) Representative samples of epididymal fat pads.
doi:10.1371/journal.pone.0006566.g002
Figure 3. Food and water intake in DLC2+/+ and DLC22/2 mice. (a) Food intake, (b) water intake, (c) feces output and (d) urine output in
24 hours. Mean values6standard errors and p-values are shown. P-values were calculated by unpaired Student’s t test.
doi:10.1371/journal.pone.0006566.g003
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detect any significant differences in food and water intake between
DLC2
2/2 mice and DLC2
+/+ mice (Figure 3).
Depletion of DLC2 did not affect cell size and
adipogenesis in MEFs
The p190B RhoGAP-deficient mouse embryos were smaller
than the wild type embryos and fibroblasts derived from the p190B
RhoGAP-deficient embryos were smaller than those derived from
wild type embryos [18]. Also, fibroblasts derived from the p190B
RhoGAP-deficient embryos were defective in adipogenesis [19].
We therefore examined whether fibroblasts derived from the
DLC2
2/2 mouse embryos were smaller in size and defective in
adipogenesis.
As demonstrated with flow cytometry, the size of the cells
derived from the DLC2
2/2 mouse embryos was not significantly
different from that of the DLC2
+/+ mouse embryos (Figure 4a and
4b). Since Sordella et al. [18] showed the AKT pathway was
downstream target of RhoA, and this eventually led to the
decreased cell size of fibroblasts derived from the p190B RhoGAP-
Figure 4. Depletion of DLC2 does not affect cell sizes. (a) Comparison of sizes of DLC2+/+ (n=6) and DLC22/2 (n=6) cells by flow cytometry.
Forward light scatter (FSC) of G1-phase-cells as determined by flow cytometry was used to measure the relative cell sizes. Mean values6standard
errors and p-values are shown. P-values were calculated by unpaired Student’s t test. (b) Representative samples of flow cytometry results. (c)
Western blot analysis of insulin-treated DLC2+/+ and DLC22/2 cells. (d) RhoA activity of DLC2+/+ and DLC22/2 cells as detected by Rhotekin
binding assay. (e) Actin cytoskeleton and focal adhesions in DLC2+/+ and DLC22/2 MEF cells were detected by immunofluorescence staining of
actin stress fibers (red) and Paxillin (green), respectively.
doi:10.1371/journal.pone.0006566.g004
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from the DLC2
2/2 and DLC2
+/+ mouse embryos. We did not
detect any difference between them in this pathway (Figure 4c).
We previously showed that DLC2 was a RhoGAP; overexpression
of DLC2 down-regulated Rho activity in hepatoma cell lines and
resulted in inhibition of actin stress fiber formation [2]. However,
up-regulation of Rho activity in the DLC2
2/2 cells was not
observed (Figure 4d) and there was some slight but not significant
difference in the formation of actin stress fibers or focal adhesions
between DLC2
2/2 and DLC2
+/+ cells (Figure 4e). These suggest
that there might be other functionally similar proteins which could
compensate the function of DLC2.
We then examined adipogenesis in fibroblasts derived from the
DLC2
2/2 and DLC2
+/+ mouse embryos. When DLC2
2/2 and
DLC2
+/+ cells were induced by standard adipocyte differentiation
induction medium, both DLC2
2/2 and DLC2
+/+ cells were
competent to differentiate into adipocytes and did not significantly
differ in lipid production quantitatively (Figure 5).
Depletion of DLC2 did not predispose to the formation
of liver tumors nor aggravate DEN-induced
hepatocarcinogenesis
We did not observe any tumor formation in the livers of the adult
DLC2
2/2 mice up to an age of 18 months. To address the role of
DLC2 in chemical-induced hepatocarcinogenesis, we treated the
15-day old maleDLC2
2/2 and DLC2
+/+ mice with DEN. When the
mice reached 35 weeks of age, they were dissected and their livers
were examined for tumor formation. We observed that liver tumors
developed in all of the mice treated with DEN. In addition, the
numbers of tumors formed and the maximal tumor diameters were
similar in both the DLC2
2/2 and DLC2
+/+ mice (p=0.79 and 0.51,
respectively)(Figure 6).These findingssuggestthatDLC2 deficiency
does not aggravate chemical hepatocarcinogenesis.
DLC1 and DLC3 mRNA expression in DLC2-depleted
tissues
Semi-quantitative PCR was performed on selected tissues
including livers, skeletal muscles and hearts of the DLC2
2/2 and
DLC2
+/+ mice at 3 months of age to observe any gene dosage
compensation by other DLC members in our DLC2
2/2 mice. Our
data showed no significant increase of either DLC1 or DLC3 in
those tissues of the DLC2
2/2 mice (Supplementary Figure S1).
The experiments were performed independently thrice.
Discussion
It was reported that DLC1-deficient embryos had neural tube
defects and died at early to midgestation [17]. As suggested by
Durkin et al. [17], this might also be due to the primary
malfunction of other organs such as the developing heart. Our
group recently showed that DLC1 negatively regulated the Rho/
ROCK [22]. Also, a relatively high level of ROCK expression was
previously observed in the developing hearts of embryos, 7.0–9.0
dpc [23] and 9.5–11.5 dpc [24]. This suggests that DLC1
deficiency may disturb the normal function of ROCK proteins in
the embryonic heart and lead to embryonic lethality. Nevertheless,
the observed phenotypes suggest that DLC1 has a critical role
during early murine development.
In this study, we showed that DLC2 deficiency did not cause any
observable developmental defects, and DLC2-deficient mice could
survive to adulthood. This suggests that the functions of DLC2 in
embryonic development may be compensated by its homolog,
DLC1, but not vice versa. It is common that paralogous genes
compensatethefunctionsofthemembersof the group.For example,
the members of mouse Hox paralogous group 3, Hoxa3, Hoxb3 and
Hoxd3, interact synergistically to regulate embryonic development
inadose-dependantmanner[25,26].AlthoughDLC2deficiencydid
not lead to embryonic lethality, DLC2-deficient mice were smaller
and had less adipose tissue. Since it was demonstrated that the
fibroblasts derived from 190B RhoGAP-deficient embryos were
smaller [18] and were less effective in adipogenesis [19], we
examined the DLC2-deficient mice along these lines. However, we
observed no significant differences in cell size and adipogenesis
betweenfibroblastsderived fromDLC2
2/2and DLC2
+/+mice.Also,
the metabolic cage experiment did not detect any significant
difference between DLC2
2/2 and DLC2
+/+ mice. In this regard,
we could not exclude the possibility that the metabolic cage
Figure 5. Depletion of DLC2 does not affect adipogenesis in MEFs. (a) Induction of adipogenesis was performed on DLC22/2 (n=6) and
DLC2+/+ (n=6) MEFs. After induction, MEFs were stained with Oil-Red O, and the stain was then extracted and absorbance at 510 nm was measured.
Mean values6standard errors and p-values are shown. P-values were calculated by unpaired Student’s t test. (b) Representative samples of Oil-Red O-
stained MEFs.
doi:10.1371/journal.pone.0006566.g005
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difference in the amount of food intake which may cause the
observed phenotype in body weight. Also we could not exclude the
fact that DLC2
2/2 mice might be more active and consumed more
calories than DLC2
+/+ mice.
It was demonstrated that DLC2 localized in the mitochon-
dria and might play a role in lipid transport [7]. In addition, it
has been suggested that the START domain containing
protein, StAR, is an essential component in steroid hormone
production in translocation of the cholesterol from the outer
membrane to the inner membrane of the mitochondria in
steroidogenic cell [27]. Since DLC2 is a START domain
containing protein and is able to localize in the mitochondria,
it will be of interest to study the physiological function of
DLC2 in relation with the lipid metabolism as well as steroid
hormone biosynthesis.
Figure 6. Depletion of DLC2 did not aggravate DEN-induced hepatocarcinogenesis. (a) Number of tumors formed in livers after DEN
treatment. (b) Size of tumor as represented by maximum diameter (in millimeters). In (a) and (b), mean values6standard errors and p-values are
shown. P-values were calculated by unpaired Student’s t test. (c) Representative liver samples treated with DEN. White arrows indicate tumors. (d)
Representative H&E stained sections of liver samples treated with DEN.
doi:10.1371/journal.pone.0006566.g006
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have tumor suppressor functions including suppression of cell
proliferation, Ras-induced colony formation and anchorage-
independent growth [1,2]. One of our primary aims in
generating the DLC2-deficient mice was to investigate the
tumor suppressor role of DLC2 in vivo. We found that DLC2
deficiency did not predispose to the formation of HCC nor
aggravate DEN-induced hepatocarcinogenesis. Again, the tumor
suppressor function of DLC2 function may be compensated by
DLC1. Since DLC1-deficient mice dies at embryonic stage, it
would be interesting to see if hepatocyte-specific deficiency of
DLC1 may predispose such mice to the development of HCC
and to delineate the role of DLC2 deficiency in the development
of HCC in these mice. It was demonstrated that loss of p53
would accelerate hepatocarcinogenesis in transgenic mice
overexpressing c-myc [29]. It would be informative to cross
DLC2-deficient mice with other knockout mice of tumor
suppressor genes, such as p53 and/or transgenic mice overex-
pressing oncogenes such as c-myc and TGF-alpha [30].
Alternatively, the newly developed system by Zender et al.
could be exploited to study the tumor suppressor role of DLC2
in hepatocarcinogenesis [31]. In that system, p53-deficient liver
progenitor cells could be infected with a combination of
ecotropic retroviruses carrying c-myc, RAS, AKT and DLC2.
This will enable us to further investigate whether DLC2 has
tumor suppressor function in vivo.
DLC2 belongs to a member of DLC family proteins. It encodes
a RhoGAP domain with high sequence homology with DLC
family members, DLC1 and DLC3. In our previous studies, we
demonstrated that DLC2 or DLC1 was able to inhibit the RhoA
activity which resulted in down regulation of actin stress fiber
formation. Furthermore, study from Kawai et al indicated that
DLC3 could also inhibit the RhoA activity by its RhoGAP
domain. Ectopic expression of DLC3 in HeLa cells decreased the
numbers of actin stress fibers [32]. The results suggest that the
functional roles of DLC1, DLC2 and DLC3 in cell lines and their
downstream effectors are quite similar. In the mouse model,
DLC1 depletion was embryonic lethal while our DLC2 knockout
mice could survive to adulthood. This suggests that the functions
of DLC2 in embryonic development may be compensated by
DLC1 or DLC3. However, from our semi-quantitative RT-PCR
result, there was no significant increase of either DLC1 or DLC3
in the livers, hearts and skeletal muscles of the DLC2 knockout
mice. The result implies that the physiological level of DLC1 or
DLC3 expression may be sufficient for the compensation of DLC2
functions. It will be interesting to generate DLC3 knockout mice to
study its significance in embryonic development and examine
whether its function can be compensated by other DLC members.
In addition, the knockout mice data indicate that the DLC
members might play different physiological roles in development.
Apart from the common downstream effector (RhoA), there might
be other different molecular targets being specifically regulated by
a particular DLC member.
Apart from studying the tumor suppressor role of DLC2 in
HCC, the DLC2-deficient mice may be useful for studying other
cancer types, as downregulation of DLC2 was also observed in
lung, ovarian, renal, breast, uterine, gastric, colon and rectal
cancers [33].
Supporting Information
Figure S1 Expression level of DLC1 and DLC3 in DLC22/2
and DLC2+/+ mice. Semi-quantitative PCR performed on the
livers, skeletal muscles and hearts of the DLC22/2 and DLC2+/
+ mice of 3 months of age showed no significant difference in the
mRNA expression levels of DLC1 and DLC3. b-actin gene was
used for normalization.
Found at: doi:10.1371/journal.pone.0006566.s001 (0.39 MB TIF)
Author Contributions
Conceived and designed the experiments: TOY IOLN. Performed the
experiments: TOY THYL SGSL OFC EKKT PLK AKML. Analyzed the
data: TOY THYL EKKT PLK SC IOLN. Contributed reagents/
materials/analysis tools: TOY THYL SC IOLN. Wrote the paper: TOY
THYL IOLN.
References
1. Ching YP, Wong CM, Chan SF, Leung TH, Ng DC, et al. (2003) Deleted in
liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor
function and is underexpressed in hepatocellular carcinoma. J Biol Chem 278:
10824–10830.
2. Leung TH, Ching YP, Yam JW, Wong CM, Yau TO, et al. (2005) Deleted in
liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of
RhoA activity. Proc Natl Acad Sci U S A 102: 15207–15212.
3. Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, et al. (1998)
Cloning, characterization, and chromosomal localization of a gene frequently
deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res
58: 2196–2199.
4. Schultz J, Ponting CP, Hofmann K, Bork P (1997) SAM as a protein interaction
domain involved in developmental regulation. Protein Sci 6: 249–253.
5. Li H, Fung KL, Jin DY, Chung SS, Ching YP, et al. (2007) Solution structures,
dynamics, and lipid-binding of the sterile alpha-motif domain of the deleted in
liver cancer 2. Proteins 67: 1154–1166.
6. Ponting CP, Aravind L (1999) START: a lipid-binding domain in StAR, HD-
ZIP and signalling proteins. Trends Biochem Sci 24: 130–132.
7. Ng DC, Chan SF, Kok KH, Yam JW, Ching YP, et al. (2006) Mitochondrial
targeting of growth suppressor protein DLC2 through the START domain.
FEBS Lett 580: 191–198.
8. Bar-Sagi D, Hall A (2000) Ras and Rho GTPases: a family reunion. Cell 103:
227–238.
9. Sahai E, Marshall CJ (2002) RHO-GTPases and cancer. Nat Rev Cancer 2:
133–142.
10. Qiu RG, Chen J, Kirn D, McCormick F, Symons M (1995) An essential role for
Rac in Ras transformation. Nature 374: 457–459.
11. Roux P, Gauthier-Rouviere C, Doucet-Brutin S, Fort P (1997) The small
GTPases Cdc42Hs, Rac1 and RhoG delineate Raf-independent pathways that
cooperate to transform NIH3T3 cells. Curr Biol 7: 629–637.
12. Ng IO, Liang ZD, Cao L, Lee TK (2000) DLC-1 is deleted in primary
hepatocellular carcinoma and exerts inhibitory effects on the proliferation of
hepatoma cell lines with deleted DLC-1. Cancer Res 60: 6581–6584.
13. Goodison S, Yuan J, Sloan D, Kim R, Li C, et al. (2005) The RhoGAP protein
DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res
65: 6042–6053.
14. Healy KD, Hodgson L, Kim TY, Shutes A, Maddileti S, et al. (2008) DLC-1
suppresses non-small cell lung cancer growth and invasion by RhoGAP-
dependent and independent mechanisms. Mol Carcinog 47: 326–337.
15. Kim TY, Lee JW, Kim HP, Jong HS, Jung M, et al. (2007) DLC-1, a GTPase-
activating protein for Rho, is associated with cell proliferation, morphology, and
migration in human hepatocellular carcinoma. Biochem Biophys Res Commun
355: 72–77.
16. Wong CM, Lee JM, Ching YP, Jin DY, Ng IO (2003) Genetic and epigenetic
alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res 63:
7646–7651.
17. Durkin ME, Avner MR, Huh CG, Yuan BZ, Thorgeirsson SS, et al. (2005)
DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is
essential for embryonic development. FEBS Lett 579: 1191–1196.
18. Sordella R, Classon M, Hu KQ, Matheson SF, Brouns MR, et al. (2002)
Modulation of CREB activity by the Rho GTPase regulates cell and organism
size during mouse embryonic development. Dev Cell 2: 553–565.
19. Sordella R, Jiang W, Chen GC, Curto M, Settleman J (2003) Modulation of
Rho GTPase signaling regulates a switch between adipogenesis and myogenesis.
Cell 113: 147–158.
20. Tybulewicz VL, Crawford CE, Jackson PK, Bronson RT, Mulligan RC (1991)
Neonatal lethality and lymphopenia in mice with a homozygous disruption of
the c-abl proto-oncogene. Cell 65: 1153–1163.
21. Todaro GJ, Green H (1963) Quantitative studies of the growth of mouse embryo
cells in cultureand their development into established lines. J Cell Biol 17: 299–313.
DLC2 and Hepatocarcinogenesis
PLoS ONE | www.plosone.org 8 August 2009 | Volume 4 | Issue 8 | e656622. Wong CC, Wong CM, Ko FC, Chan LK, Ching YP, et al. (2008) Deleted in
liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in
hepatocellular carcinoma. PLoS ONE 3: e2779.
23. Wei L, Roberts W, Wang L, Yamada M, Zhang S, et al. (2001) Rho kinases play
an obligatory role in vertebrate embryonic organogenesis. Development 128:
2953–2962.
24. Zhao Z, Rivkees SA (2003) Rho-associated kinases play an essential role in
cardiac morphogenesis and cardiomyocyte proliferation. Dev Dyn 226: 24–32.
25. Manley NR, Capecchi MR (1997) Hox group 3 paralogous genes act
synergistically in the formation of somitic and neural crest-derived structures.
Dev Biol 192: 274–288.
26. Manley NR, Capecchi MR (1998) Hox group 3 paralogs regulate the
development and migration of the thymus, thyroid, and parathyroid glands.
Dev Biol 195: 1–15.
27. Stocco DM (2001) StAR protein and the regulation of steroid hormone
biosynthesis. Annu Rev Physiol 63: 193–213.
28. Xiaorong L, Wei W, Liyuan Q, Kaiyan Y (2008) Underexpression of deleted in
liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor
prognosis in hepatocellular carcinoma. BMC Cancer 8: 205.
29. Klocke R, Bartels T, Jennings G, Brand K, Halter R, et al. (2001) Lack of p53
accelerates hepatocarcinogenesis in transgenic mice constitutively overexpressing
c-myc in the liver. FASEB J 15: 1404–1406.
30. Santoni-Rugiu E, Jensen MR, Factor VM, Thorgeirsson SS (1999) Acceleration
of c-myc-induced hepatocarcinogenesis by Co-expression of transforming
growth factor (TGF)-alpha in transgenic mice is associated with TGF-beta1
signaling disruption. Am J Pathol 154: 1693–1700.
31. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, et al. (2006)
Identification and validation of oncogenes in liver cancer using an integrative
oncogenomic approach. Cell 125: 1253–1267.
32. Kawai K, Kiyota M, Seike J, Deki Y, Yagisawa H (2007) START-GAP3/DLC3
is a GAP for RhoA and Cdc42 and is localized in focal adhesions regulating cell
morphology. Biochem Biophys Res Commun 364: 783–789.
33. Ullmannova V, Popescu NC (2006) Expression profile of the tumor suppressor
genes DLC-1 and DLC-2 in solid tumors. Int J Oncol 29: 1127–1132.
DLC2 and Hepatocarcinogenesis
PLoS ONE | www.plosone.org 9 August 2009 | Volume 4 | Issue 8 | e6566